The BoB jury comprises esteemed experts from the fields of science, industry, and finance and is responsible for selecting the competition’s winners from the pre-selected finalists.
If your project ranks among the top three in your category, you will be invited to personally pitch your business idea to the jury. All presenting teams will receive comprehensive feedback from the BoB jury.
To ensure confidentiality, all jury members are required to sign a strict confidentiality agreement.
Elisabeth Klager
Administrative Director, LBI Digital Health and Patient Safety
Elisabeth Klager has a business background with a focus on innovation and strategy management.
From 2014 to 2019 she worked in Vienna and Hamburg for an international health technology company in the field of business development for telemedicine and digital health solutions.
In October 2019, she joined the board of the newly founded Ludwig Boltzmann Institute Digital Health and Patient Safety as Administrative Director, where she is also responsible for the research approach "Open Innovation in Science".
Currently, she is pursuing a PhD in telemedicine and empowerment at the Medical University of Vienna's Center for Public Health.
Reinhard Krickl
Venture Partner at Hadean Ventures
In 25 years in the Medical Device Industry, Reinhard has gained extensive experience in developing Med-Tech innovation into successful businesses – 14 years in the big corporate world in various international leadership positions within Medtronic; from 2014 ten years as CEO of Phagenesis, a Europe & US based neurostim start-up, for which he raised over 70m and drove the company from product to full commercialisation creating a new market in Europe and the US.
To round up his profile Reinhard is now working as Venture Partner at Hadean Ventures, does strategy consulting and is chairperson in Boards of Med-Tech start-ups to help young businesses to develop.
Alongside his industry experience Reinhard holds an Executive MBA from IMD Lausanne, an M.Sc. (Dipl.-Ing.) in Electrical Engineering from Vienna University of Technology, and the Certificate in Corporate Governance IDP-C from INSEAD Fontainebleau.
Regina Hodits
Managing Director at Angelini Ventures
Regina recently joined Angelini Ventures as Managing Director, where she is now leading the international BioTech investment strategy for this dynamic corporate venture firm. Before, she has been a Managing Partner at Wellington Partners Life Sciences (WPLS) and represented the WPLS funds on the Boards of Minervax, Seamless, Sidekick Health, SNIPR Biome, and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), invested in Themis Medical (acquired by MSD). In addition, she serves on the Board of the BII BioInnovation Institute, is the Chairperson in of the Vienna university founders organization inits and is a member of the advisory group for KfW Capital and the SME council of the German Ministry of Economics BMWK.
Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star, and Jenavalve, and served on several Boards, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (became part of Horizon Pharma NASDAQ: HRZN), Shanghai-based Novamed, and has been an external director at GlaxoSmithKline’s Respiratory TA Board. Before, Regina worked for Apax Partners, and started to build her extensive network in the global healthcare industry during her tenure at McKinsey. In the 90s, Regina gained initial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.
Joachim Rothe
Partner at EQT Life Sciences
Joachim (JR) Rothe, PhD, joined EQT Life Sciences in 2002. His prime focus and responsibility within EQT is to invest in unlisted securities and the general management of the firm. Prior to joining EQT, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Hoffmann-La Roche in Switzerland.
Joachim brings a strong scientific background and in-depth knowledge of the pharmaceutical and biotechnology industries to the EQT team. He has been appointed a Director of a large number of companies, all of which he has helped to grow by leveraging his scientific expertise, pharmaceutical experience and global networks. Among others, Joachim is currently a Director at Nouscom, Ariceum, and Innovative Molecules.
Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. He has authored numerous articles in leading scientific publications, including Nature.
Angelika Weinländer-Mölders
Weinländer-Mölders professional career began as a sales rep after studying Chemistry in Karlsruhe and Berkeley.
She has more than 15 years of experience in medical technology, especially in the dermatological and ophthalmological environment in positions as managing director, business unit director and commercial director in start-ups, medium-sized companies and corporations. Added to this is four years of experience in the chemical distribution market and over 8 years of experience as a managing director in the pharmaceutical industry.
Dr. Angelika Weinländer-Mölders is a generalist manager with a focus on sales, marketing, business development and an expert in setting up and restructuring business units.
Since the end of 2022, Ms. Weinländer-Mölders has retired from management tasks for family reasons and is making her competence and experience available as a Key Account Manager to a leading IT company in the public transport industry.
Michael Wolzt
Michael Wolzt, MD. Born 1967 in Vienna, Austria, he graduated from Vienna University and received his MD in 1991. He is Professor of Medicine at the Medical University of Vienna and senior consultant at the Vienna General Hospital. His career spans specialist training in internal medicine, clinical pharmacology, cardiology, and diabetes & metabolism at the Vienna General Hospital, and post-graduate training at the University College London, UK.
He is head of Cardiovascular Medicine at the Department of Clinical Pharmacology, Director of the Clinical Trials Coordination Centre (KKS), and is named European expert to the EMA. Michael Wolzt has been partner in IMI projects, FP7 and H2020 consortia, and in the Erasmus programme.
The scientific interest covers different clinical aspects of inflammation, vascular function, thrombosis, and metabolism. He has published more than 350 original articles in peer-reviewed journals, has authored several books and has jointly organised post-graduate training programmes.
